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Abstract
Mullerian adenosarcoma with sarcomatous overgrowth (MASO) is a rare variant of uterine
sarcomas, associated with postoperative recurrence, metastases and a fatal outcome. The mean
age at diagnosis is 54.5 years. A 37-year-old nullipara presented with irregular vaginal bleeding, a
normal pelvic examination, and an initially negative ultrasound. Repeat ultrasound one month later
revealed an 11-cm heterogeneous pelvic mass. She underwent total abdominal hysterectomy and
bilateral salpingo-oophorectomy. Pathology confirmed uterine MASO. Computed tomography 2
weeks postoperatively showed a huge mass compatible with recurrence. Patient died 2 weeks later.
MASO is rarely diagnosed in women in their 4th decade. This case stresses that these aggressive
tumors should be considered in the differential of patients with vaginal bleeding and pelvic masses
irrespective of their age.
Background
Uterine sarcomas generally account for less than 4% of all
uterine malignancies with the subtype adenosarcoma
comprising only 8% of cases, reflecting the rarity of this
entity [1]. Mullerian adenosarcoma with sarcomatous
overgrowth (MASO) is a rare variant of uterine adenosar-
comas first described in 1989 [2] and usually occurs in the
sixth decade of life [3]. We report a 37-year-old woman
who was diagnosed with MASO and died within a month
of diagnosis.
Case history
A 37-year-old nullipara, previously healthy, presented
with a 3-month history of irregular heavy menstrual
bleeding. Ultrasound of the pelvis showed normal pelvic
structures and the absence of any masses. Shortly after-
wards, she started to report dull left lower quadrant
abdominal pain, increased abdominal girth, and malo-
dorous greenish vaginal discharge. A repeat ultrasound
performed a month later showed a huge amount of
abdominal ascites and a heterogeneous formation meas-
uring ~11 cm in the pelvis. Liver, pancreas, kidney, spleen
and bladder were normal. Abdominal tap was done and
bloody fluid was aspirated. Cytology of the fluid showed
numerous malignant cells. A computed tomography (CT)
of the abdomen and pelvis revealed a big heterogeneous
tumor in the pelvis with thickening and irregularity of the
peritoneum.
The patient underwent a total abdominal hysterectomy
with bilateral salpingooophorectomy and omentectomy.
A 3-kg tumor floating in the peritoneum was evacuated.
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Histology of the polypoid mass revealed a biphasic tumor
composed of benign epithelial elements and a sarcoma-
tous stroma (Figure 1). Most of these large benign cysti-
cally dilated endometrial glands were cuffed by a packed
hypercellular layer of malignant stromal cells (Figure 2).
The stromal component arised from the endometrial
stroma and was admixed with foci of undifferentiated
cells with large polygonal, elongated and round hyper-
chromatic nuclei with very high mitotic figures (up to 18/
10 HPF), many of which were bizarre and atypical. Also
noted were abundant scattered plumped large round cells
with deeply eosinophilic cytoplasm and eccentric nuclei
resembling rhabdomyoblasts (Figure 3). Areas of pure sar-
coma were abundant. The stroma contained abundant
network of capillary-type blood vessels. Foci of necrosis
and abundant hemorrhage were seen. Abundant lym-
phatic permeation of small sarcomatous tissue was noted
within the tumor bulk. The tumor invaded into the inner
half of the myometrium and focal extension into the
stroma of the endocervix was noted.
A panel of immunohistochemical stains, including
smooth muscle actin (SMA), muscle specific actin (MSA),
desmin, S-100, CD10, multiCK, epithelial membrane
antigen (EMA), and vimentin were performed and cells
were positive for MSA and vimentin. The findings were
consistent with MASO. The sarcoma was of the undiffer-
entiated endometrial stromal type with rhabdomyosarco-
matous differentiation. Two weeks later, the patient's
abdomen increased in size again. Ultrasound of the abdo-
men showed a huge mass, and tumor recurrence was con-
sidered. Spiral CT revealed extensive peritoneal
carcinomatosis. Patient died after 2 weeks of disease recur-
rence before adjuvant therapy could be administered.
Discussion
Mullerian adenosarcomas of the uterus rarely present in
premenopausal women. It is even more unusual to diag-
nose the rare variant MASO in this age group with a
Low power: A biphasic tumor composed of benign epithelial elements and a sarcomatous str aFigure 1
Low power: A biphasic tumor composed of benign epithelial 
elements and a sarcomatous stroma.
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High Power: Many of these large benign cystically dilated 
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stromal cells (thick arrow). The epithelial component con-
sists of scattered irregular dilated benign endometrial glands 
lined by a single layer of low columnar epithelium (thin 
arrow).
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common presenting symptom is abnormal vaginal bleed-
ing (71%) ranging from spotting to menorrhagia, as in
our patient. One can argue that a uterine curettage for the
3-month history of heavy and irregular vaginal bleeding
would have resulted in an earlier diagnosis of her disease.
However, whether this would have had any implications
on the prognosis remains unanswered.
These tumors can present as a pelvic mass (37%), uterine
polyp (22%), or an enlarged uterus (22%) [4]. Pain, foul
smelling vaginal discharge, or symptoms of pelvic pres-
sure have also been reported. Risk factors that have been
associated with an increased risk of uterine adenosarcoma
include unopposed estrogen stimulation [5], long term
oral contraceptive use [6], and prolonged use of
tamoxifen for breast cancer [7,8]. Our patient had none of
these risk factors.
A review by Krivak et al revealed 37 cases of MASO
described in the literature up to 2001 [3]. MASO has a
benign glandular component and a malignant sarcoma-
tous component that constitutes more than 25% of the
tumor [9]. It may have a heterologous sarcoma compo-
nent; that is the sarcomatous component is derived from
tissue not native to the uterus, such as cartilage, osteoid
and striated muscle [10], of which the rhabdomyosar-
coma is the most common as was noted in our patient.
The presence of heterologous elements, especially rhab-
domyosarcoma may represent a more clinically aggressive
tumor [11]. The histologic finding of sarcomatous over-
growth is a predictor of poor prognosis while deep myo-
metrial invasion is considered a predictor of aggressive
behavior [12].
ASSO are considered high grade, have a high mitotic rate,
and are DNA aneuploid with an S-phase fraction >10%
[13]. The fact that the ultrasound done at onset of symp-
toms failed to detect any pelvic or abdominal mass, while
an ultrasound done a month later showed a large 11 cm
mass reflects the high mitotic rate observed in such
tumors, and raises the question of how frequent should
radiological and clinical follow up be performed in
patients with high grade aggressive tumors such as MASO.
In contrast to typical Mullerian adenosarcomas of the
uterus, MASO are more aggressive tumors, frequently
associated with postoperative recurrence (25%) or metas-
tases, and have a fatal outcome [8]. Recurrence and metas-
tasis were reported to occur even in early stages of the
disease. In cases of recurrence, the interval between detec-
tion of the initial and the recurring tumors is no less than
9 months [9].
Cornerstone of therapy of uterine sarcomas remains sur-
gery. Total abdominal hysterectomy with bilateral salp-
ingo-oophorectomy (TAHBSO) can be curative if disease
was confined to the uterus with five-year survival
approaching 50% [14]. Adjuvant radiotherapy appears to
have a role in better pelvic control and decrease in local
recurrence of the tumor [15]. However, improvement in
survival is still controversial [15,16]. Data regarding the
benefit of adjuvant chemotherapy is very controversial,
especially with the paucity of studies and lack of control.
The chemotherapeutic agents consist of either doxoru-
bicin or a combination of cisplatin and ifosfamide with
mesna [3]. Intraperitoneal disease may be treated with
whole abdomen radiation or chemotherapy. Ovarian con-
servation in women of reproductive age with Mullerian
adenocarcinoma is an option in cases of non-metastatic
disease, confined to the uterus [17]. The overall median
survival time of patients with uterine MASO is 13 months
[2]. Survival of patients with MASO can be as short as 1
month even after surgery and adjuvant therapy [3]. Our
patient's tumor recurred two weeks after the resection of
the initial mass which highlights the necessity of extensive
debulking surgery with removal of all possible tumor
implants and the need to initiate postoperative adjuvant
therapy for better control of disease and prevention of
recurrence. Whether the 2-week delay in initiation of
adjuvant therapy, or the failure to remove all lesions by
the debulking surgery resulted in early recurrence of the
disease in our patient cannot be known.
The rarity of such tumors in young age groups makes the
clinical suspicion very low, resulting in delay in making
the diagnosis, and with highly proliferative tumors, rate of
complications is expected to increase as seen in our
patient who presented with extensive peritoneal metasta-
sis. Whether a repeat ultrasound performed at a shorter
interval would have detected the tumor at an earlier stage
before it grows and spreads is to be considered. In addi-
tion, due to the rarity of adenosarcomas there is no con-
sensus regarding therapy. A study dealing with the time of
initiation of postoperative adjuvant therapy in relation to
the interval to tumor recurrence is further needed to out-
line recommendations regarding promptness of adjuvant
therapy and its effect on survival, tumor progression, and
disease free period.
In conclusion, gynecologists, pathologists, and oncolo-
gists should be aware of the consequences associated with
a delay in the diagnosis and/or initiation of therapy for
Mullerian adenosarcoma with sarcomatous overgrowth.
Although rare, this entity should be kept in the differential
of young women presenting with abnormal menstrual
bleeding in the presence of a pelvic mass.
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